Please assess the completion status of the following clinical trial:

Trial Title: V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Virginal Female Subject Aged 9 To 17 Years~Exclusion Criteria:~* Male Subject

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle \[VLP\] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).